Earlier in April LIDDS announced a new project, a Toll-Like Receptor 9 (TLR9) formulated with the NanoZolid platform. Positive preclinical data have been generated so far and LIDDS aims to start Phase I in 2020. We have included the new project in our valuation which raising our valuation range slightly.

Download research report

Jakob Svensson

Equity Analyst

LIDDS: Another (potential) weapon against cancer

Redeye Research Update timeStamp 2 months ago

Tagged companies

You need to be a Redeye member to access this content

Become a member to:

Redeye Research Update 2 months ago